DURECT Corp (DRRX):企業の財務・戦略的SWOT分析

◆英語タイトル:DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME305FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

DURECT Corp (DRRX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

DURECT Corp (Durect) is a biopharmaceutical company that focuses on research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. It also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.

DURECT Corp Key Recent Developments

Mar 05,2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25,2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March 4
Jan 04,2021: DURECT announces closing of LACTEL Absorbable Polymer Product Line sale to Evonik and receipt of $15 million
Nov 02,2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02,2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
DURECT Corp – Key Facts
DURECT Corp – Key Employees
DURECT Corp – Key Employee Biographies
DURECT Corp – Major Products and Services
DURECT Corp – History
DURECT Corp – Company Statement
DURECT Corp – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
DURECT Corp – Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
DURECT Corp – Corporate Strategy
DURECT Corp – SWOT Analysis
SWOT Analysis – Overview
DURECT Corp – Strengths
DURECT Corp – Weaknesses
DURECT Corp – Opportunities
DURECT Corp – Threats
DURECT Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 05, 2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25, 2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March 4
Nov 02, 2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02, 2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer
Aug 03, 2020: DURECT announces second quarter 2020 financial results and update of programs
May 12, 2020: DURECT announces first quarter 2020 financial results and update of programs
May 05, 2020: DURECT receives loan under Paycheck Protection Program
Mar 03, 2020: DURECT announces fourth quarter and full year 2019 financial results and update of programs
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
DURECT Corp, Key Facts
DURECT Corp, Key Employees
DURECT Corp, Key Employee Biographies
DURECT Corp, Major Products and Services
DURECT Corp, History
DURECT Corp, Key Competitors
DURECT Corp, Ratios based on current share price
DURECT Corp, Annual Ratios
DURECT Corp, Annual Ratios (Cont...1)
DURECT Corp, Interim Ratios
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[DURECT Corp (DRRX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ferrovial SA (FER):企業の財務・戦略的SWOT分析
    Ferrovial SA (FER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Inova Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inova Diagnostics Inc (Inova), a subsidiary of Werfen Life Group SAU is a medical device company that develops and commercializes new autoimmune technologies and diagnostic markers. The company's diagnostic reagent products include quanta flash used for semi-quantitative determination of aut …
  • Integrated Device Technology Inc (IDTI):企業の財務・戦略的SWOT分析
    Integrated Device Technology Inc (IDTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Harbin Bank Co Ltd:企業の戦略・SWOT・財務分析
    Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Harbin Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Applus Services, S.A.:企業のM&A・事業提携・投資動向
    Applus Services, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Applus Services, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Games Workshop Group PLC (GAW):企業の財務・戦略的SWOT分析
    Summary Games Workshop Group PLC (Games Workshop) is a miniature wargaming products manufacturing company. The company designs, manufactures and distributes fantasy miniatures, metal soldiers and rule books. Its products include warhammer age of sigmar, warhammer 40000, the hobbit, scenery, painting …
  • Cowen Inc:企業の戦略・SWOT・財務情報
    Cowen Inc - Strategy, SWOT and Corporate Finance Report Summary Cowen Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Fiat Chrysler Automobiles NV:戦略・SWOT・企業財務分析
    Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report Summary Fiat Chrysler Automobiles NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Luxshare Precision Industry Co., Ltd. (002475):企業の財務・戦略的SWOT分析
    Luxshare Precision Industry Co., Ltd. (002475) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Eurobio Scientific SA (ALERS):企業の製品パイプライン分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …
  • Bacardi Ltd:企業の戦略的SWOT分析
    Bacardi Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Oil and Natural Gas Corporation Limited:企業の戦略・SWOT・財務分析
    Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Oil and Natural Gas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • APRIL Group S.A. (APR):企業の財務・戦略的SWOT分析
    APRIL Group S.A. (APR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Taiga Building Products Ltd (TBL):企業の戦略的SWOT分析
    Taiga Building Products Ltd (TBL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • ResApp Health Ltd (RAP):製薬・医療:M&Aディール及び事業提携情報
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • Enzon Pharmaceuticals Inc (ENZN):製薬・医療:M&Aディール及び事業提携情報
    Summary Enzon Pharmaceuticals Inc (Enzon), formerly Enzon, Inc., is a pharmaceutical company that receives royalty revenues from existing licensing arrangements. The company has licensing arrangements with other companies related to sales of their four marketed drug products, namely, PegIntron, Syla …
  • Vertex Pharmaceuticals Incorporated:企業の戦略・SWOT・財務分析
    Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report Summary Vertex Pharmaceuticals Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Noble Corporation Plc (NE):企業の財務・戦略的SWOT分析
    Noble Corporation Plc (NE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆